Katherine Lajkosz

Katherine Lajkosz

Auto-generated profile, based on publicly available information

Katherine Lajkosz

University Health Network 3 Department of Biostatistics Toronto, Canada

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2022 in Radiology
Verified
Journal Article
Closed access
SGSangeet Ghai
Sangeet Ghai
NPNathan Perlis
Nathan Perlis
CAChantal Atallah
Chantal Atallah
SJSarah Jokhu
Sarah Jokhu
KCKateri Corr
Kateri Corr
MHMasoom A. Haider
Masoom A. Haider
Multiparametric MRI and micro-US showed similar prostate cancer detection rates in biopsy-naive men; although micro-US was inferior to multiparametric MRI for biopsy avoidance, most MRI lesions wer... Background Multiparametric MRI has led to increased detection of clinically significant prostate cancer (csPCa). Micro-US is being investigated for csPCa detection. Purpose To compare multiparametr...

1 October 2018 in Injury
Verified
Journal Article
Closed access
SMSteve Mann
Steve Mann
DBDaniel Banaszek
Daniel Banaszek
KLKatherine Lajkosz
Katherine Lajkosz
SBSusan B. Brogly
Susan B. Brogly
SSShelby M. Stanojev
Shelby M. Stanojev
SHStephen Hall
Stephen Hall

1 July 2017 in Journal of Palliative Care
Verified
Journal Article
Closed access
SMShaila J. Merchant
Shaila J. Merchant
KLKatherine Lajkosz
Katherine Lajkosz
SBSusan B. Brogly
Susan B. Brogly
CBChristopher M. Booth
Christopher M. Booth
SNSulaiman Nanji
Sulaiman Nanji
Nancy Noel BaxterNancy Noel Baxter
Nancy Noel Baxter
Studies have reported overly aggressive end-of-life care (EOLC) in many cancers. We investigate trends in, and factors associated with, aggressive EOLC among patients who died of gastrointestinal (GI) cancers in Ontario, Canada. All patients with primary cause of death from esophageal, gastric, colon, and anorectal cancer from January 2003 to December 2013 were identified through the Ontario Cancer Registry, and information was collected from linked databases. Outcomes representing aggressive EOLC were assessed: administration of chemotherapy, any emergency department (ED) visits, hospital admissions, intensive care unit (ICU) admissions (all within 30 days of death), death in hospital and in ICU, and a composite outcome representing any aggressive EOLC. Temporal trends were analyzed using the Cochran-Armitage test. There were 34 630 patients in the cohort: 43% colon, 26% anorectal, 19% gastric, and 12% esophageal cancers. Aggressive EOLC was delivered to 65%, with a significantly decreasing trend from 64.8% in 2003 to 62.5% in 2013 (P = .001). Utilization of specific elements of aggressive EOLC included 8% chemotherapy, 46% ED visits, 49% hospital admissions, 6% ICU admissions, 45% death in hospital, and 5% death in ICU. Trends over the study period showed that ED visits (from 43% to 46.9%; P = .0001) and death in ICU (from 3.7% to 4.9%; P = .04) significantly increased; hospital admissions (from 48.9% to 47.8%; P = .02) and death in hospital (from 46.6% to 38.9%; P < .0001) significantly decreased. Two-thirds of patients with GI cancer had aggressive EOLC in the last 30 days of life.

30 November 2022 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
VJViranda H. Jayalath
Viranda H. Jayalath
RCRoderick Keir Clark
Roderick Keir Clark
KLKatherine Lajkosz
Katherine Lajkosz
RFRouhi Fazelzad
Rouhi Fazelzad
NFNeil E. Fleshner
Neil E. Fleshner
RHRobert J. Hamilton
Robert J. Hamilton
Importance: Epidemiological evidence supports a role for statins in improving survival in advanced prostate cancer, particularly among men receiving androgen-ablative therapies.Objective: To study the association between statin use and survival among men with prostate cancer receiving androgen deprivation therapy (ADT) or androgen receptor axis–targeted therapies (ARATs).Data Sources: This systemic review and meta-analysis used sources from MEDLINE, EMBASE, Epub Ahead of Print, Cochrane Clinical Trials, Cochrane Systematic Reviews, and Web of Science from inception to September 6, 2022.Study Selection: Observational studies reporting associations of concurrent statin use and survival outcomes (in hazard ratios [HRs]).Data Extraction and Synthesis: Two authors independently abstracted all data. Summary estimates pooled multivariable HRs with 95% CIs using the generic inverse variance method with random-effects modeling. A priori specified subgroup and sensitivity analyses were undertaken, and heterogeneity, study quality, and publication bias were evaluated. Confidence in the evidence was assessed using the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) approach.Main Outcomes and Measures: Overall mortality and prostate cancer–specific mortality (PCSM).Results: Twenty-five cohorts of 119 878 men (65 488 statin users [55%]) with more than 74 416 deaths were included. Concurrent statin use was associated with a 27% reduction in the risk of overall mortality (HR, 0.73 [95% CI, 0.66-0.82]; I2 = 83%) and a 35% reduction in the risk of PCSM (HR, 0.65 [95% CI, 0.58-0.73]; I2 = 74%), with substantial heterogeneity in both estimates. Subgroup analyses identified a PCSM advantage associated with statins for men receiving ARATs compared with ADT alone (HR, 0.40 [95% CI, 0.30-0.55] vs 0.68 [95% CI, 0.60-0.76]; P = .002 for difference). Confidence in the evidence was rated low for both outcomes.Conclusions and Relevance: The findings of this meta-analysis show that concurrent statin use was associated with reduced overall mortality and PCSM among men receiving androgen-ablative therapies for advanced prostate cancer. These findings are limited by the observational nature of the data and residual unexplained interstudy heterogeneity. Randomized clinical trials are warranted to validate these results.

1 November 2020 in Urologic Oncology: Seminars and Original Investigations
Verified
Journal Article
Closed access
TJTristan Juvet
Tristan Juvet
Andrea MariAndrea Mari
Andrea Mari
KLKatherine Lajkosz
Katherine Lajkosz
CWChristopher Wallis
Christopher Wallis
CKCynthia Kuk
Cynthia Kuk
AZAlexandre R. Zlotta
Alexandre R. Zlotta

13 July 2023 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
NFNeil E. Fleshner
Neil E. Fleshner
RSRashid K. Sayyid
Rashid K. Sayyid
AHAaron R. Hansen
Aaron R. Hansen
JCJoseph L. K. Chin
Joseph L. K. Chin
Ricardo FernandesRicardo Fernandes
Ricardo Fernandes
AJAnthony Joshua
Anthony Joshua
Purpose: Early treatment intensification with neoadjuvant therapy may improve outcomes in patients with high-risk, localized prostate cancer treated with radical prostatectomy. Our objective was to compare pathologic, oncologic, and safety outcomes of neoadjuvant abiraterone acetate plus leuprolide acetate with or without cabazitaxel prior to radical prostatectomy in patients with localized, high-risk prostate cancer. Patients and Methods: This open-label, multicenter, phase II trial randomized men with clinically localized, D'Amico high-risk prostate cancer to neoadjuvant abiraterone acetate (1,000 mg/day) and leuprolide acetate (22.5 mg every 3 months) with or without cabazitaxel (25 mg/m2) prior to radical prostatectomy. The primary outcome was pathologic complete response (pCR) or minimal residual disease (MRD). Secondary outcomes included surgical margins, lymph node involvement, pathologic stage, 12-month biochemical relapse-free survival (BRFS) rates, and safety profile. Results: The per-protocol population consisted of 70 patients [cabazitaxel arm (Arm A): 37, no cabazitaxel arm (Arm B): 33]. Median patient age and prostate-specific antigen levels were 63.5 years [interquartile range (IQR), 58.0–68.0] and 21.9 ng/mL (IQR, 14.6–42.8), respectively. pCR/MRD occurred in 16 (43.2%) versus 15 patients (45.5%) in arms A and B, respectively (P = 0.85). pCR occurred in two (5.4%) versus three patients (9.1%) in arms A and B, respectively (P = 0.66). Patients with ≤ 25% total biopsy cores positive had increased odds of pCR/MRD (P = 0.04). Patients with pCR/MRD had superior 12-month BRFS rates (96.0% vs. 62.0%, P = 0.03). Grade 3+ adverse events occurred in 42.5% and 23.7% of patients in arms A and B, respectively (P = 0.078). Conclusions: Neoadjuvant cabazitaxel addition to abiraterone acetate/leuprolide acetate prior to radical prostatectomy did not improve pCR/MRD in clinically localized, high-risk prostate cancer.